Xufeng WEI, with a doctoral degree, graduated from the Department of Cardiology at the Fourth Military Medical University. He is an associate professor and a master's supervisor. I have visited and studied at Thomas Jefferson University in the United States, and conducted postdoctoral research at the University of Maryland. Later, I served as an assistant professor of surgery at the university's medical center and a part-time associate professor at the Asia Pacific Medical Center in the United States. Current Chairman and Chief Scientist of Jiangsu Meifengli Medical Technology Co., Ltd., Chairman of Suzhou GoldenWing Medical Technology Co., Ltd., Deputy Director of the Department of Cardiology and Director of the Research Department at Wuxi Mingci Cardiovascular Hospital, Professor of Industry and Master's Supervisor at Nanjing Medical University.

He has been engaged in clinical, scientific research, and teaching work in cardiac surgery for a long time. He has served as a resident physician, attending physician, associate professor, and laboratory manager in the cardiac surgery department of Xijing Hospital of the Fourth Military Medical University. Led the research and development of multiple important artificial organs in cardiac surgery, including biological heart valves, artificial hearts, and artificial lungs. Hosted 9 research projects, including sub projects of the National 863 Program, general projects of the National Natural Science Foundation, youth funds, key projects of the military logistics research, and general projects of social development in Jiangsu Province, with a total research funding of over 10 million yuan. Published multiple SCI papers, including 13 as first author or corresponding author, with a highest impact factor of 29.69 points, and a total of 8 as one or co author. Participated in the writing of 2 monographs and holds multiple invention patents. In 2019, participated in the project of "Establishment and Application of New Technologies and Medical Service Treatment Strategies for Severe Chest Trauma on the Battlefield" and won the second prize of National Science and Technology Progress Award.

He has been selected as a high-level entrepreneurial talent team in the "113 Talent Plan" of China Medical City, a "Double Innovation Talent" plan in Jiangsu Province, a "Double Innovation Team" talent in Jiangsu Province, a leading talent in science and technology innovation and entrepreneurship in Suzhou High tech Zone, a leading talent in innovation and entrepreneurship in Gusu, a third level training object of the sixth "333 High level Talent Training Project" in Jiangsu Province, a young and middle-aged expert with outstanding contributions in Taizhou City, and one of the "Top Ten Entrepreneurial Figures" in Taizhou City. He concurrently holds academic positions such as Vice Chairman of the Medical Animal Experiment Expert Committee of the Chinese Research Hospital Association, Vice President of the Animal Industry Research and Biological Evaluation Branch of the National Health Industry Enterprise Management Association, and National Committee Member of the Extracorporeal Life Support Branch of the Chinese Society of Cardiothoracic Anesthesia.

After returning to China, he led a team to complete preclinical animal experiments on more than 30 innovative products, including implantable artificial hearts, the first extracorporeal artificial heart, and interventional heart valves in China. He has accumulated rich experience in the development and evaluation of cardiovascular medical devices, clinical applications, scientific research management, laboratory management, and start-up company management, and is a senior expert in the development and evaluation of medical devices in the cardiovascular field.